KALARIS THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Diluted
KALARIS THERAPEUTICS, INC. (KLRS) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$58.77 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-03-07
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-12-31 was -$18.27M.
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$4.13M.
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was -$6.08M.
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2024-03-31 was -$30.30M.
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$58.77M.
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$190.42M.
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$168.71M.
- KALARIS THERAPEUTICS, INC. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$171.96M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -$18.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$22.39M derived: sum of 2 quarters · filed 2025-03-07 | -$28.47M derived: sum of 3 quarters · filed 2025-03-07 | -$58.77M 10-K · filed 2025-03-07 | |
| 2024-09-30 | -$4.13M 10-Q · filed 2024-11-12 | -$10.20M derived: sum of 2 quarters · filed 2024-11-12 | -$40.50M 10-Q · filed 2024-11-12 | -$100.20M derived: sum of 4 quarters · filed 2025-03-07 | |
| 2024-06-30 | -$6.08M 10-Q · filed 2024-08-09 | -$36.38M 10-Q · filed 2024-08-09 | -$96.07M derived: sum of 3 quarters · filed 2025-03-07 | -$140.34M derived: sum of 4 quarters · filed 2025-03-07 | |
| 2024-03-31 | -$30.30M 10-Q · filed 2024-05-13 | -$90.00M derived: sum of 2 quarters · filed 2025-03-07 | -$134.27M derived: sum of 3 quarters · filed 2025-03-07 | -$179.53M derived: sum of 4 quarters · filed 2025-03-07 | |
| 2023-12-31 | -$59.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$103.97M derived: sum of 2 quarters · filed 2025-03-07 | -$149.24M derived: sum of 3 quarters · filed 2025-03-07 | -$190.42M 10-K · filed 2025-03-07 | |
| 2023-09-30 | -$44.27M 10-Q · filed 2024-11-12 | -$89.54M derived: sum of 2 quarters · filed 2024-11-12 | -$130.72M 10-Q · filed 2024-11-12 | -$168.86M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | -$45.27M 10-Q · filed 2024-08-09 | -$86.45M 10-Q · filed 2024-08-09 | -$124.59M derived: sum of 3 quarters · filed 2024-08-09 | -$166.66M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | -$41.18M 10-Q · filed 2024-05-13 | -$79.32M derived: sum of 2 quarters · filed 2024-05-13 | -$121.39M derived: sum of 3 quarters · filed 2024-05-13 | -$166.03M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$38.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$80.21M derived: sum of 2 quarters · filed 2024-03-15 | -$124.85M derived: sum of 3 quarters · filed 2024-03-15 | -$168.71M 10-K · filed 2024-03-15 | |
| 2022-09-30 | -$42.07M 10-Q · filed 2023-11-02 | -$86.71M derived: sum of 2 quarters · filed 2023-11-02 | -$130.57M 10-Q · filed 2023-11-02 | -$188.51M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | -$44.64M 10-Q · filed 2023-08-03 | -$88.50M 10-Q · filed 2023-08-03 | -$146.44M derived: sum of 3 quarters · filed 2023-08-03 | -$191.95M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | -$43.86M 10-Q · filed 2023-05-04 | -$101.80M derived: sum of 2 quarters · filed 2023-05-04 | -$147.31M derived: sum of 3 quarters · filed 2023-05-04 | -$184.90M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | -$57.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | -$103.45M derived: sum of 2 quarters · filed 2023-02-15 | -$141.04M derived: sum of 3 quarters · filed 2023-02-15 | -$171.96M 10-K · filed 2023-02-15 | |
| 2021-09-30 | -$45.51M 10-Q · filed 2022-11-03 | -$83.10M derived: sum of 2 quarters · filed 2022-11-03 | -$114.02M 10-Q · filed 2022-11-03 | -$139.31M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$37.59M 10-Q · filed 2022-08-04 | -$68.51M 10-Q · filed 2022-08-04 | -$93.80M derived: sum of 3 quarters · filed 2022-08-04 | -$117.41M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$30.92M 10-Q · filed 2022-05-05 | -$56.21M derived: sum of 2 quarters · filed 2022-05-05 | -$79.83M derived: sum of 3 quarters · filed 2022-05-05 | -$91.46M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$25.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$48.90M derived: sum of 2 quarters · filed 2022-02-10 | -$60.53M derived: sum of 3 quarters · filed 2022-02-10 | -$69.87M 10-K · filed 2022-02-10 | -$69.78M 10-K · filed 2021-02-12 |
| 2020-09-30 | -$23.61M 10-Q · filed 2021-11-05 | -$35.25M derived: sum of 2 quarters · filed 2021-11-05 | -$44.59M 10-Q · filed 2021-11-05 | -$53.33M derived: sum of 4 quarters · filed 2021-11-05 | |
| 2020-06-30 | -$11.63M 10-Q · filed 2021-08-06 | -$20.97M 10-Q · filed 2021-08-06 | -$29.71M derived: sum of 3 quarters · filed 2021-08-06 | -$36.98M derived: sum of 4 quarters · filed 2021-08-06 | |
| 2020-03-31 | -$9.34M 10-Q · filed 2021-05-06 | -$18.08M derived: sum of 2 quarters · filed 2021-05-06 | -$25.35M derived: sum of 3 quarters · filed 2021-05-06 | -$30.65M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | -$8.74M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | -$16.01M derived: sum of 2 quarters · filed 2021-02-12 | -$21.32M derived: sum of 3 quarters · filed 2021-02-12 | -$23.84M 10-K · filed 2021-02-12 | |
| 2019-09-30 | -$7.27M 10-Q · filed 2020-11-10 | -$12.57M derived: sum of 2 quarters · filed 2020-11-10 | -$15.10M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$5.30M 10-Q · filed 2020-09-02 | -$7.83M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |